Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.

Annals of hematology - 1 Feb 2010

Nachnani Jagdish S, Rao Gowtham A, Bulchandani Deepti, Pandya Prashant K, Alba Laura M

Abstract excerpt

Hematological abnormalities including neutropenia, anemia, and thrombocytopenia are commonly seen in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The aim of this study was to identify factors which would help to predict the development of hematological abnormalities in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. During a 4-year period,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Hematologic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Multivariate Analysis

Share to Neutropenia

Share to Ribavirin

Share to Thrombocytopenia

Source

Identifiers

PMID: 19565241
DOI: 10.1007/s00277-009-0774-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.PMID 19565241Read ↗

Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.Semantic proximity Read ↗

Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.Semantic proximity Read ↗

Pharmacogenetics of ribavirin-induced anemia in HCV patients.Semantic proximity Read ↗

[A study of the relationship between neutropenia and clinical infection risk during treatment with peginterferon alfa-2a and ribavirin for chronic hepatitis C].Semantic proximity Read ↗

Ribavirin in the treatment of chronic hepatitis C.Semantic proximity Read ↗

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.Semantic proximity Read ↗

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.Semantic proximity Read ↗

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.Semantic proximity Read ↗

Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.Semantic proximity Read ↗

Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.